Great news for the Pulmonary Hypertension (PH) community! Through the Canadian Drug Agency's (CDA) funding initiative for rare diseases,...

As most PH clinics are in large cities, PH patients living in rural or remote areas and who must travel long distances to their clinic...

We are pleased to announce that sotatercept, a new drug for patients diagnosed with pulmonary arterial hypertension (PAH), is now listed...

Tune in to the latest episode of the PHaware podcast, where Dr. Jason Weatherald, a pulmonologist at the University of Alberta, delves...

The US Food and Drug Administration (FDA) has granted approval for the medication sotatercept, a significant milestone in the treatment...

In treatment trials for pulmonary arterial hypertension, looking at clinical events as outcomes instead of just 6-minute walk distance...

PHA Canada's very own Dr. Sanjay Metha, Dr. Lisa Mielniczuk, and others have published a study in the European Respiratory Review. Read...

About Advances in Pulmonary Hypertension magazine: Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension...

Clinicians at 17 US pulmonary hypertension centres were interviewed about their understanding of social determinants of health in...

This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...

In February, the panCanadian Pharmaceutical Alliance entered into formal pricing negotiations with the manufacturer of Opsyvni...

This small study examined the use of social media by parents and caregivers of children with pulmonary hypertension. Seventy percent of...

In other diseases, palliative care is associated with better quality of life, symptom management, illness understanding, and reduced...

This pilot study added apabetalone to people's PAH therapy twice daily for 16 weeks to see if a future clinical trial evaluating...